Manufacturer record
R.P. Biotech Pvt. Ltd. 61: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
5 batches manufactured by R.P. Biotech Pvt. Ltd. 61 (Punjab) were declared Not of Standard Quality between September 2025 and September 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
5 records linked to R.P. Biotech Pvt. Ltd. 61 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| RAXOFEN Ibuprofen and Paracetamol Tablets IP | 6563Mfg 2025-04 · Exp 2027-03 | sample does not conform to claim as per IP 2022 in respect to the Test of Dissolution of Paracetamol, Dissolution of IbuprofenDissolution | RDTL, ChandigarhCDSCO lab | Sep 2025 |
| PANZOLE Pantoprazole Sodium Tablets I.P. | 6735Mfg 2025-06 · Exp 2027-05 | sample does not conform to claim as per IP 2022 and Addendum 2024 in respect to the Test of Dissolution (Buffer Stage)Dissolution | RDTL, ChandigarhCDSCO lab | Sep 2025 |
| Loperamide Hydrochloride Capsules IP 2 mg | 7645Mfg 2025-03 · Exp 2027-02 | sample does not conform to claim as per IP 2022 in respect to the Test of DissolutionDissolution | RDTL, ChandigarhCDSCO lab | Sep 2025 |
| Cyproheptadine Tablets IP 4 mg | 6489Mfg 2025-03 · Exp 2027-02 | sample does not conform to claim as per IP 2022 in respect to the Assay of Cyproheptadine HydrochlorideAssay | RDTL, ChandigarhCDSCO lab | Sep 2025 |
| AMLOCARE-AT Amlodipine and Atenolol Tablets IP | 6717Mfg 2025-06 · Exp 2027-05 | sample does not conform to claim as per IP 2022 in respect to the Assay of Amlodipine Besylate Calculated As Amlodipine, AtenololAssay | RDTL, ChandigarhCDSCO lab | Sep 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.